Regulatory and effector functions of gamma–delta (γδ) T cells and their therapeutic potential in adoptive cellular therapy for cancer
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
γδ T cells are an important innate immune component of the tumor microenvironment and are known to affect the immune response in a wide variety of tumors. Unlike αβ T cells, γδ T cells are capable of spontaneous secretion of IL‐17A and IFN‐γ without undergoing clonal expansion. Although γδ T cells do not require self‐MHC‐restricted priming, they can distinguish “foreign” or transformed cells from healthy self‐cells by using activating and inhibitory killer Ig‐like receptors. γδ T cells were used in several clinical trials to treat cancer patient due to their MHC‐unrestricted cytotoxicity, ability to distinguish transformed cells from normal cells, the capacity to secrete inflammatory cytokines and also their ability to enhance the generation of antigen‐specific CD8+ and CD4+ T cell response. In this review, we discuss the effector and regulatory function of γδ T cells in the tumor microenvironment with special emphasis on the potential for their use in adoptive cellular immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394 · cited 1×
“Tumor cells have an active mevalonate pathway(53) and produce isoprenoids such as IPP, which help in cell growth and survival.(54) Many of the mevalonate pathway intermediates, including IPP, were shown to activate human Vg9Vd2 T cells and promote anti-tumor response.”
BackgroundImmunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis
Coffelt, S. B., Kersten, K., Doornebal, C. W., Weiden, J., Vrijland, K., Hau, C.-S., Verstegen, N. J. M., Ciampricotti, M., Hawinkels, L. J. A. C., Jonkers, J., et al. (2015) · Nature · doi:10.1038/nature14282 · Cited by 1,703
Thornton, A. M., Korty, P. E., Tran, D. Q., Wohlfert, E. A., Murray, P. E., Belkaid, Y., & Shevach, E. M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0904028 · Cited by 1,382
Immunogenic and tolerogenic cell death
Green, D. R., Ferguson, T., Zitvogel, L., & Kroemer, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2545 · Cited by 1,176 · cited 1×
“During chemotherapy, dying tumor cells can prime immune cells (immunogenic cell death) and induce immune tolerance (tolerogenic cell death).(98) A deficiency of gd T cells had been reported in several malignancies such as breast cancer(99) and hematological,(100) liver(99) and gastric(101) tumors, suggesting that adop…”
BackgroundRibot, J. C., deBarros, A., Pang, D. J., Neves, J. F., Peperzak, V., Roberts, S. J., Girardi, M., Borst, J., Hayday, A. C., Pennington, D. J., et al. (2009) · Nature Immunology · doi:10.1038/ni.1717 · Cited by 628
Wu, P., Wu, D., Ni, C., Ye, J., Chen, W., Hu, G., Wang, Z., Wang, C., Zhang, Z., Xia, W., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.03.013 · Cited by 608
Diversity of murine gamma genes and expression in fetal and adult T lymphocytes
Heilig, J. S., & Tonegawa, S. (1986) · Nature · doi:10.1038/322836a0 · Cited by 448
Ye, J., Ma, C., Hsueh, E. C., Eickhoff, C. S., Zhang, Y., Varvares, M. A., Hoft, D. F., & Peng, G. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202369 · Cited by 203
The Inhibitory Receptor BTLA Controls γδ T Cell Homeostasis and Inflammatory Responses
Bekiaris, V., Šedý, J. R., Macauley, M. G., Rhode-Kurnow, A., & Ware, C. F. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.017 · Cited by 95
Cited by
CD56 in the Immune System: More Than a Marker for Cytotoxicity?
Van Acker, H. H., Capsomidis, A., Smits, E. L., & Van Tendeloo, V. F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00892 · Cited by 388
Gamma-delta (γδ) T cells: friend or foe in cancer development?
Zhao, Y., Niu, C., & Cui, J. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-017-1378-2 · Cited by 298
T cell-mediated immunity to malaria
Kurup, S. P., Butler, N. S., & Harty, J. T. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0158-z · Cited by 242
Galland, S., & Stamenkovic, I. (2020) · The Journal of Pathology · doi:10.1002/path.5357 · Cited by 165
“γδ T cells have the ability to produce the pro-inflammatory cytokines IFN-γ, TNF-α, and IL-17, as well as the anti-inflammatory cytokines TGF-β, IL-4, and IL-10, depending on the types of signals that predominate in the tissue microenvironment, and exert both anti- and pro-tumoral effects [158].”
BackgroundGamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment
Gao, Z., Bai, Y., Lin, A., Jiang, A., Zhou, C., Cheng, Q., Liu, Z., Chen, X., Zhang, J., & Luo, P. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01722-0 · Cited by 138
Giri, S., & Lal, G. (2021) · Molecular Immunology · doi:10.1016/j.molimm.2021.06.006 · Cited by 37
Self-citationCharacterization of γδ T cells in patients with non-small cell lung cancer
Bao, Y., Guo, L., & Mo, J. (2017) · Oncology Letters · doi:10.3892/ol.2017.6191 · Cited by 14
Metadata
- Authors
- Paul, S., & Lal, G.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2016-04-15
- Volume
- 139
- Issue
- 5
- Pages
- 976-985
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2304674697
- Cited by
- 105
- References
- 10
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.